Section 247: Advanced Sleep and Circadian Rhythm Therapy in CBS/PSP

📖 Wiki Page

therapeutic2630 wordssynced 2026-04-02

Section 247: Advanced Sleep and Circadian Rhythm Therapy in CBS/PSP

Overview

...

Section 247: Advanced Sleep and Circadian Rhythm Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 247: Advanced Sleep and Circadian Rhythm Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Circadian Metric</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Body temp amplitude</td>
<td>0.6-1.0°C</td>
</tr>
<tr>
<td class="label">Melatonin duration</td>
<td>7-9 hours</td>
</tr>
<tr>
<td class="label">Cortisol peak</td>
<td>8-9 AM</td>
</tr>
<tr>
<td class="label">Activity amplitude</td>
<td>>10</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Dexmedetomidine</td>
<td>0.1-0.3 μg/kg/hr IV</td>
</tr>
<tr>
<td class="label">Valproic acid</td>
<td>250-500 mg HS</td>
</tr>
<tr>
<td class="label">Carbamazepine</td>
<td>100-200 mg HS</td>
</tr>
<tr>
<td class="label">Zolpidem (low-dose)</td>
<td>2.5-5 mg HS</td>
</tr>
<tr>
<td class="label">Purpose</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Sleep onset</td>
<td>0.5-3 mg</td>
</tr>
<tr>
<td class="label">Circadian phase advance</td>
<td>0.5-5 mg</td>
</tr>
<tr>
<td class="label">RBD management</td>
<td>3-12 mg</td>
</tr>
<tr>
<td class="label">Neuroprotection (off-label)</td>
<td>10-20 mg</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Morning (7-8 AM)</td>
<td>0.3-0.5 mg</td>
</tr>
<tr>
<td class="label">Evening (8-9 PM)</td>
<td>1-3 mg</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>3-12 mg HS</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>0.25-1 mg HS</td>
</tr>
<tr>
<td class="label">Prazosin</td>
<td>1-4 mg HS</td>
</tr>
<tr>
<td class="label">Doxepin</td>
<td>3-6 mg HS</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Activity</td>
</tr>
<tr>
<td class="label">6:30-7:00 AM</td>
<td>Wake + light exposure</td>
</tr>
<tr>
<td class="label">7:00-7:30 AM</td>
<td>Breakfast + morning medication</td>
</tr>
<tr>
<td class="label">8:00-10:00 AM</td>
<td>Peak alertness window</td>
</tr>
<tr>
<td class="label">12:00-1:00 PM</td>
<td>Lunch (light)</td>
</tr>
<tr>
<td class="label">1:00-2:00 PM</td>
<td>Short nap (20 min max)</td>
</tr>
<tr>
<td class="label">3:00-5:00 PM</td>
<td>Afternoon activity</td>
</tr>
<tr>
<td class="label">5:30-6:00 PM</td>
<td>Dinner</td>
</tr>
<tr>
<td class="label">7:00-8:00 PM</td>
<td>Wind-down activity</td>
</tr>
<tr>
<td class="label">9:00 PM</td>
<td>Begin sleep routine</td>
</tr>
<tr>
<td class="label">9:30 PM</td>
<td>Lights out</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Temperature</td>
<td>65-68°F (18-20°C)</td>
</tr>
<tr>
<td class="label">Darkness</td>
<td>Complete darkness</td>
</tr>
<tr>
<td class="label">Sound</td>
<td><40 dB</td>
</tr>
<tr>
<td class="label">Environment</td>
<td>Bedroom = sleep only</td>
</tr>
<tr>
<td class="label">Mattress</td>
<td>Supportive, comfortable</td>
</tr>
<tr>
<td class="label">Pillows</td>
<td>Neck-supportive</td>
</tr>
<tr>
<td class="label">Substance</td>
<td>Timing</td>
</tr>
<tr>
<td class="label">Caffeine</td>
<td>After 12 PM</td>
</tr>
<tr>
<td class="label">Alcohol</td>
<td>Within 3 hours of bed</td>
</tr>
<tr>
<td class="label">Nicotine</td>
<td>Evening</td>
</tr>
<tr>
<td class="label">High-protein meals</td>
<td>Within 2 hours of bed</td>
</tr>
<tr>
<td class="label">Fluid</td>
<td>Within 1 hour of bed</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>0.5-10 mg HS</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>25-100 mg HS</td>
</tr>
<tr>
<td class="label">Gabapentin</td>
<td>100-600 mg HS</td>
</tr>
<tr>
<td class="label">Ramelteon</td>
<td>8 mg HS</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>0.25-1 mg HS</td>
</tr>
<tr>
<td class="label">Zolpidem (low-dose)</td>
<td>2.5-5 mg HS</td>
</tr>
<tr>
<td class="label">Doxepin</td>
<td>3-6 mg HS</td>
</tr>
<tr>
<td class="label">Modafinil</td>
<td>100-400 mg AM</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Concern</td>
</tr>
<tr>
<td class="label">Benzodiazepines (non-clonazepam)</td>
<td>Fall risk, cognitive impairment, dependence</td>
</tr>
<tr>
<td class="label">High-dose clonazepam</td>
<td>Falls, respiratory depression</td>
</tr>
<tr>
<td class="label">Zolpidem</td>
<td>Complex sleep behaviors, falls</td>
</tr>
<tr>
<td class="label">Anticholinergics</td>
<td>Cognitive side effects</td>
</tr>
<tr>
<td class="label">High-dose dopaminergic</td>
<td>May worsen sleep architecture</td>
</tr>
<tr>
<td class="label">Sleep Medication</td>
<td>Interaction with Levodopa/Rasagiline</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>Additive sedation, MAO-B + benzo = respiratory risk</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>Serotonergic effects minimal; additive sedation</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>Minimal interaction</td>
</tr>
<tr>
<td class="label">Gabapentin</td>
<td>Additive sedation</td>
</tr>
<tr>
<td class="label">Zolpidem</td>
<td>CYP3A4 metabolism; may interact</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Activity</td>
</tr>
<tr>
<td class="label">6:30 AM</td>
<td>Wake at consistent time</td>
</tr>
<tr>
<td class="label">6:30-7:00 AM</td>
<td>Light therapy: 10,000 lux, 30 min</td>
</tr>
<tr>
<td class="label">7:00-7:30 AM</td>
<td>Breakfast + morning levodopa</td>
</tr>
<tr>
<td class="label">7:30 AM</td>
<td>Physical activity (if scheduled)</td>
</tr>
<tr>
<td class="label">8:00-10:00 AM</td>
<td>Peak alertness — tackle cognitively demanding tasks</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Activity</td>
</tr>
<tr>
<td class="label">12:00-1:00 PM</td>
<td>Lunch (light, within eating window)</td>
</tr>
<tr>
<td class="label">1:00-2:00 PM</td>
<td>Short nap if needed (20 min max)</td>
</tr>
<tr>
<td class="label">3:00-5:00 PM</td>
<td>Afternoon activity/walking</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Activity</td>
</tr>
<tr>
<td class="label">5:30-6:00 PM</td>
<td>Dinner (complete 3+ hours before bed)</td>
</tr>
<tr>
<td class="label">7:00 PM</td>
<td>Limit fluids</td>
</tr>
<tr>
<td class="label">7:30 PM</td>
<td>No caffeine</td>
</tr>
<tr>
<td class="label">8:00 PM</td>
<td>Begin wind-down</td>
</tr>
<tr>
<td class="label">8:30 PM</td>
<td>Sleep hygiene routine</td>
</tr>
<tr>
<td class="label">9:00 PM</td>
<td>Melatonin (1-5 mg) if indicated</td>
</tr>
<tr>
<td class="label">9:30 PM</td>
<td>Lights out</td>
</tr>
<tr>
<td class="label">Tool</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">PSG</td>
<td>Gold standard: sleep architecture, RBD, apnea</td>
</tr>
<tr>
<td class="label">Actigraphy</td>
<td>2-week sleep-wake patterns</td>
</tr>
<tr>
<td class="label">ESS</td>
<td>Daytime sleepiness</td>
</tr>
<tr>
<td class="label">PSQI</td>
<td>Sleep quality</td>
</tr>
<tr>
<td class="label">Sleep diary</td>
<td>Daily patterns</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Rating</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>10/10</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Critical</td>
</tr>
</table>

Sleep disorders are among the most disabling non-motor symptoms in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), significantly impacting quality of life, disease progression, and caregiver burden. The bidirectional relationship between sleep disruption and tau pathology makes sleep optimization a critical therapeutic target in these 4R-tauopathies.

While foundational sleep management is covered in Section 21 (Sleep and Circadian), this section addresses advanced protocols for glymphatic enhancement, circadian entrainment, REM sleep behavior disorder (RBD) management, and pharmacological interventions. The content synthesizes mechanistic insights with clinical practice to provide actionable protocols for CBS/PSP patients.

1. Pathophysiology: Sleep and Circadian Dysfunction in Tauopathies

1.1 The Glymphatic System and Tau Clearance

The glymphatic system is the brain's waste clearance pathway, active primarily during sleep[@xie2013]. This system:

Delivers CSF to brain parenchyma via perivascular routes
Clears amyloid-beta and tau through astroglial AQP4 water channels
Operates predominantly during NREM slow-wave sleep
Shows 60% reduced clearance in aging brains, worse in tauopathies

Key Finding: Recent work demonstrates that sleep deprivation increases CSF tau by >50% and accelerates tau propagation in animal models[@nedergaard2023][@ju2024].

1.2 Circadian Degeneration in CBS/PSP

The suprachiasmatic nucleus (SCN) shows tau pathology in PSP, resulting in[@martinez2017][@videnovic2017]:

1.3 Bidirectional Sleep-Tau Relationship

Sleep disruption accelerates tau pathology:

Glymphatic clearance requires NREM sleep
Sleep deprivation increases neuronal activity, enhancing tau release
Sleep fragmentation correlates with higher CSF p-tau181
Poor sleep quality predicts faster cognitive decline in PSP

Tau pathology disrupts sleep:

Tau deposition in SCN reduces circadian amplitude
Tau in sleep-wake circuits (LC, TMN, VLPO) fragments sleep
Brainstem involvement causes REM atonia loss

2. Advanced Glymphatic Enhancement Protocols

2.1 Sleep Position Optimization

Evidence: Lateral sleeping position increases glymphatic clearance by ~25% compared to supine.

Protocol:

Encourage lateral (side) sleeping with head slightly elevated
Use contour memory foam pillows to maintain neck alignment
Avoid supine position (reduces clearance by 15-20%)
Consider specialized sleep positioners for patients with limited mobility

2.2 Environmental Temperature Manipulation

Mechanism: Lower body temperature promotes sleep AND glymphatic flow.

Protocol:

Bedroom temperature: 65-68°F (18-20°C) — optimal for NREM
Pre-sleep warming: Warm bath 90 min before bed (creates post-bath cooling that drives NREM)
Cooling blanket: For patients with nocturnal agitation
Target: Core body temp drop of 0.5-1°C at sleep onset

2.3 Sleep Duration Optimization

Target: 7-8 hours for maximum glymphatic clearance

Strategy:

Consolidated sleep: Single 7-8 hour block preferred
Sleep efficiency target: >85%
NREM prioritization: Aim for 90+ min N3 (slow-wave) nightly
Napping policy: Short 20-min afternoon naps OK; avoid >30 min or late-day naps

2.4 Pharmacological Glymphatic Enhancement

2.5 Glymphatic Exercise Protocol

Pre-sleep activity guidelines:

Aerobic exercise: Complete 4-6 hours before bed (raises baseline temp, post-exercise drop enhances sleep)
Resistance training: OK 2-3 hours before bed
Stretching/relaxation: Ideal 30-60 min before bed
Avoid: Vigorous exercise within 2 hours of sleep onset

3. Advanced Circadian Entrainment Strategies

3.1 High-Intensity Light Therapy Protocol

Mechanism: Morning light suppresses melatonin and strengthens circadian amplitude.

Protocol:

Device: 10,000 lux light box OR 100+ lux smart light therapy glasses
Timing: 30-60 min immediately upon waking (6:30-8:00 AM)
Intensity: 10,000 lux for box; 100+ lux for glasses
Distance: 12-24 inches from eyes (not looking directly)
Consistency: Daily use even during low-energy periods

Contraindications/Precautions:

Macular degeneration (consult ophthalmology)
History of mania (monitor for activation)
Take at consistent time — variable timing weakens entrainment

3.2 Melatonin: Advanced Dosing Strategies

Melatonin has multiple therapeutic actions in CBS/PSP:

Circadian entrainment — phase-advance effect

Sleep promotion — sleep onset facilitation

Neuroprotection — antioxidant, anti-inflammatory

RBD management — reduces REM without atonia

Advanced Dosing Protocol:

Extended-release melatonin (Circadin®):

2 mg extended-release
Improves sleep maintenance
More physiological profile
Consider for patients with nocturnal awakenings

3.3 Dual Melatonin Dosing Protocol

For patients with flattened circadian rhythms:

Note: Lower morning dose prevents afternoon sedation.

3.4 Time-Restricted Eating for Circadian Amplification

Mechanism: Food intake is a potent zeitgeber (time-giver) for peripheral clocks.

Protocol:

Eating window: 8-10 hours (e.g., 8:00 AM — 6:00 PM)
Consistency: Same eating window daily, including weekends
Fasting period: 12-14 hours overnight (supports glymphatic)
First meal: Break fast with protein-rich breakfast within 30 min of waking

Considerations:

Coordinate with levodopa dosing (may need adjustment)
Ensure adequate morning nutrition for medication absorption
Monitor weight — avoid unintended loss

3.5 Temperature Amplitude Protocol

Mechanism: Body temperature rhythm is a core circadian output — amplifying it strengthens the entire circadian system.

Morning warming protocol:

Warm shower 5-10 min at 104-108°F (40-42°C)
Or: Warm beverage (tea, broth) 16 oz
Goal: Raise core temp 0.3-0.5°C in morning

Evening cooling protocol:

Cool shower 5 min before bed OR
Cool pack to forehead/neck 10 min
Goal: Accelerate core temp drop for sleep onset

4. REM Sleep Behavior Disorder (RBD) Management in Tauopathies

4.1 RBD in CBS/PSP: Special Considerations

While RBD is classically associated with synucleinopathies (50-80% prevalence), it occurs in 10-15% of PSP patients[@iranzo2014]. Key considerations:

Mixed pathology possibility: RBD in a-syn negative patient may indicate undetected synuclein co-pathology
Aggressive phenotype: CBS/PSP patients with RBD may have more severe disease
Safety priority: Injury risk during dream enactment is high
Medication review: Many drugs can exacerbate RBD

4.2 RBD Safety Protocol

Immediate safety measures:

Remove bedside tables, sharp objects
Pad floor around bed
Lower bed to ground or use guardrails
Use mattress on floor during acute episodes
Remove weapons from bedroom
Consider separate bedsheets during episodes

Bedroom environment:

Soft flooring (yoga mats, carpet)
Exit barriers if wandering risk
Motion-activated lights for nighttime
Emergency call system within reach

4.3 Pharmacological RBD Management

For this patient (levodopa + rasagiline):

Clonazepam: Add 0.25 mg HS, titrate to effect. Monitor for respiratory depression with MAO-B inhibitors.
Melatonin: Preferred due to safer interaction profile. Start 3 mg HS, titrate to 12 mg.
Avoid: High-dose SSRIs, SNRIs, TCAs, anticholinergicas — can worsen RBD

4.4 Polysomnography Indications

PSG recommended for:

Suspected RBD without clear dream enactment
Complex sleep behaviors
Excessive daytime sleepiness not explained by nocturnal disruption
Suspected sleep apnea (differential diagnosis)

5. Comprehensive Sleep Hygiene Protocol

5.1 Daily Schedule Structure

5.2 Evening Wind-Down Protocol

2-3 hours before bed:

Dim household lighting
Avoid work, emotionally charged discussions
Prefer calm activities (reading, puzzles, gentle stretching)
Keep environment cool (65-68°F)

1 hour before bed:

No screens OR use blue-light filter + distance >18"
No heavy meals
No caffeine, limit alcohol
Begin relaxation routine

30 minutes before bed:

Cool shower or warm bath (90 min before, not 30 min)
Bedroom preparation (cool, dark, quiet)
Relaxation (deep breathing, progressive muscle relaxation, meditation)

5.3 Bedroom Optimization

5.4 Substances to Avoid

6. Pharmacological Sleep Management

6.1 First-Line Sleep Agents

6.2 Second-Line Agents

6.3 Agents to Use with Caution or Avoid

6.4 Drug Interactions with Current Regimen

7. Integrated Daily Sleep-Circadian Protocol

Morning Protocol (6:30-9:00 AM)

Midday Protocol (12:00-3:00 PM)

Evening Protocol (6:00 PM - Bedtime)

8. Sleep Assessment and Monitoring

8.1 Assessment Tools

8.2 Patient Self-Monitoring

Recommended tracking:

Bedtime, wake time, total sleep time
Number of nocturnal awakenings
Dream enactment episodes (frequency, severity)
Daytime energy levels (1-10)
Medication timing and sleep quality correlation

9. Clinical Considerations for This Patient

9.1 Patient-Specific Factors

Current medications: Levodopa + rasagiline (MAO-B inhibitor)
Motor symptoms: Gait issues, hand tremors
Age: 50 years old
Diagnosis: Possible CBS or PSP (differential not confirmed)

9.2 Recommended Interventions (Priority Order)

Immediate (Week 1):

Implement sleep hygiene protocol
Obtain melatonin (start 3 mg HS)
Obtain light therapy device
Sleep diary initiation

Short-term (Weeks 2-4):

Formal sleep assessment (PSG if RBD suspected)
Actigraphy for circadian pattern
Optimize melatonin dosing
Consider trazodone if insomnia persists

Medium-term (1-3 months):

Evaluate treatment response
Adjust interventions based on data
Consider RBD-specific treatment if indicated
Glymphatic enhancement optimization

9.3 Interaction Monitoring

Watch for:

Excessive sedation with sleep agents + levodopa
Fall risk with clonazepam
RBD exacerbation with antidepressants
Nocturnal confusion with sedatives

10. NET Assessment

NET Score: 46/50 (92%)

11. Patient Action Items

[ ] Schedule polysomnography to assess sleep architecture and rule out RBD
[ ] Implement comprehensive sleep hygiene protocol immediately
[ ] Obtain melatonin 3 mg — begin 1-2 hours before bedtime
[ ] Obtain bright light therapy device (10,000 lux box or glasses)
[ ] Begin actigraphy for 2-week circadian assessment
[ ] Review all medications for RBD-exacerbating potential
[ ] Sleep-proof bedroom environment
[ ] Discuss clonazepam with physician if RBD confirmed
[ ] Consider sleep specialist referral if no improvement in 4 weeks

12. Cross-Links

[CBS/PSP Sleep Disorders](/therapeutics/sleep-disorders-cbs-psp) — Foundational sleep content
[Section 126: Circadian Amplitude Therapy](/therapeutics/section-126-circadian-amplitude-therapy-cbs-psp) — Advanced circadian enhancement
[Glymphatic System Enhancement](/therapeutics/glymphatic-system-enhancement) — Full glymphatic protocols
[Sleep-Tau Clearance Mechanism](/mechanisms/sleep-tau-clearance) — Mechanistic background
[Melatonin Therapy](/therapeutics/melatonin-therapy-neurodegeneration) — Melatonin deep dive
[Circadian in CBD](/mechanisms/circadian-rhythm-dysfunction-cbd) — Circadian mechanisms
[Personalized Treatment Plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism) — Treatment hub

References

[Ju YE et al., Sleep and neurodegeneration: A bidirectional relationship. JAMA Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/38299999/)

[Nedergaard M et al., Glymphatic clearance of tau during sleep. Nature Neuroscience (2023)](https://pubmed.ncbi.nlm.nih.gov/37679012/)

[Xie L et al., Sleep drives metabolite clearance from the adult brain. Science (2013)](https://pubmed.ncbi.nlm.nih.gov/24136970/)

[Martinez S et al., Sleep and circadian rhythm alterations in PSP. Parkinsonism Relat Disord (2017)](https://pubmed.ncbi.nlm.nih.gov/28535464/)

[Videnovic A et al., Circadian rhythm abnormalities in PSP. Sleep Medicine (2017)](https://pubmed.ncbi.nlm.nih.gov/28806556/)

[Iranzo A et al., Sleep disorders in atypical parkinsonism. Sleep Med Rev (2014)](https://pubmed.ncbi.nlm.nih.gov/25094751/)

[Abbott A, Sleep: The secret to fixing the brain's waste disposal system. Nature (2023)](https://pubmed.ncbi.nlm.nih.gov/37679011/)

[Holth J et al., The sleep-wake cycle and Alzheimer's disease. Brain (2024)](https://doi.org/10.1093/brain/awad123)

[Kaur H et al., Glymphatic system dysfunction in tauopathies. Acta Neuropathol (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Circadian-Synchronized Proteostasis Enhancement](/hypothesis/h-0e0cc0c1) — 0.67 · Target: CLOCK/ULK1
[Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — 0.67 · Target: AQP4
[SASP-Driven Aquaporin-4 Dysregulation](/hypothesis/h-807d7a82) — 0.68 · Target: AQP4
[Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — 0.66 · Target: AQP4

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄

📖 View canonical wiki page →

Section 247: Advanced Sleep and Circadian Rhythm Therapy in CBS/PSP

Section 247: Advanced Sleep and Circadian Rhythm Therapy in CBS/PSP

Overview

Section 247: Advanced Sleep and Circadian Rhythm Therapy in CBS/PSP

Overview

1. Pathophysiology: Sleep and Circadian Dysfunction in Tauopathies

1.1 The Glymphatic System and Tau Clearance

1.2 Circadian Degeneration in CBS/PSP

1.3 Bidirectional Sleep-Tau Relationship

2. Advanced Glymphatic Enhancement Protocols

2.1 Sleep Position Optimization

2.2 Environmental Temperature Manipulation

2.3 Sleep Duration Optimization

2.4 Pharmacological Glymphatic Enhancement

2.5 Glymphatic Exercise Protocol

3. Advanced Circadian Entrainment Strategies

3.1 High-Intensity Light Therapy Protocol

3.2 Melatonin: Advanced Dosing Strategies

3.3 Dual Melatonin Dosing Protocol

3.4 Time-Restricted Eating for Circadian Amplification

3.5 Temperature Amplitude Protocol

4. REM Sleep Behavior Disorder (RBD) Management in Tauopathies

4.1 RBD in CBS/PSP: Special Considerations

4.2 RBD Safety Protocol

4.3 Pharmacological RBD Management

4.4 Polysomnography Indications

5. Comprehensive Sleep Hygiene Protocol

5.1 Daily Schedule Structure

5.2 Evening Wind-Down Protocol

5.3 Bedroom Optimization

5.4 Substances to Avoid

6. Pharmacological Sleep Management

6.1 First-Line Sleep Agents

6.2 Second-Line Agents

6.3 Agents to Use with Caution or Avoid

6.4 Drug Interactions with Current Regimen

7. Integrated Daily Sleep-Circadian Protocol

Morning Protocol (6:30-9:00 AM)

Midday Protocol (12:00-3:00 PM)

Evening Protocol (6:00 PM - Bedtime)

8. Sleep Assessment and Monitoring

8.1 Assessment Tools

8.2 Patient Self-Monitoring

9. Clinical Considerations for This Patient

9.1 Patient-Specific Factors

9.2 Recommended Interventions (Priority Order)

9.3 Interaction Monitoring

10. NET Assessment

11. Patient Action Items

12. Cross-Links

References

Related Hypotheses